SAN JOSE, Calif.--(BUSINESS WIRE)--DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, today announced the first U.S. patient was successfully treated using the Spinal Tumor Ablation with Radiofrequency (STAR™) System. The FDA-commercially cleared, percutaneous Targeted RadioFrequency Ablation (t-RFA™) device delivers energy directly into a metastatic vertebral body tumor to heat and destroy tumor cells and provide palliative pain relief.
